| Literature DB >> 36131071 |
Yuanshuai Su1, Chengzhi Li2, Yu Fang1, Xinyu Gu1, Qiuxian Zheng1, Juan Lu3, Lanjuan Li4.
Abstract
Increasingly advanced biology technique has revealed that long non-coding RNAs (lncRNA) as critical factors that exert significant regulatory effects on biological functions by modulating gene transcription, epigenetic modifications and protein translation. A newly emerging lncRNA, ladybird homeobox 2 (LBX2)-antisense RNA 1 (LBX2-AS1), was found to be highly expressed in various tumors. Moreover, it is functionally linked to the regulation of essential tumor-related biological processes, such as cell proliferation and apoptosis, through interactions with multiple signaling molecules/pathways. The important roles played by LBX2-AS1 in cancer initiation and progression suggest that this lncRNA has enormous clinical potential for use as a novel biomarker or therapeutic target. In this article, we retrospectively review the latest advances in research exploring the roles of the lncRNA LBX2-AS1 in oncology field, highlighting its involvement in a comprehensive network of molecular mechanisms underlying diverse cancers and examining its potential applications in clinical practice.Entities:
Keywords: Cancer therapy; LBX2-AS1; Long noncoding RNA; Molecular mechanism; Oncogenic
Year: 2022 PMID: 36131071 DOI: 10.1007/s12094-022-02944-2
Source DB: PubMed Journal: Clin Transl Oncol ISSN: 1699-048X Impact factor: 3.340